Key Takeaways & Executive Findings
- •• RTCB deficiency in mouse colon disrupts intestinal barrier integrity and induces inflammatory cell infiltration, leading to colitis. • RTCB knockout activates the NF-κB pathway, evidenced by increased TNF-α, IL-8, and p-p65, and decreased IKKβ and IκBα. • RTCB deficiency suppresses the Wnt/β-catenin pathway, with reduced Wnt3a, β-catenin, and LGR5, and increased GSK3β. • The study provides novel insights into RTCB's role in colonic homeostasis and suggests potential therapeutic targets for colitis.
Abstract
RNA terminal phosphorylase B (RTCB) has been shown to play a significant role in multiple physiological processes. However, the specific role of RTCB in the mouse colon remains unclear. In this study, we employ a conditional knockout mouse model to investigate the effects of RTCB depletion on the colon and the potential molecular mechanisms. We assess the efficiency and phenotype of Rtcb knockout using PCR, western blot analysis, histological staining, and immunohistochemistry. Compared with the control mice, the Rtcb-knockout mice exhibit compromised colonic barrier integrity and prominent inflammatory cell infiltration. In the colonic tissues of Rtcb-knockout mice, the protein levels of TNF-α, IL-8, and p-p65 are increased, whereas the levels of IKKβ and IκBα are decreased. Moreover, the level of GSK3β is increased, whereas the levels of Wnt3a, β-catenin, and LGR5 are decreased. Collectively, our findings unveil a close association between RTCB and colonic tissue homeostasis and demonstrate that RTCB deficiency can lead to dysregulation of both the NF-κB and Wnt/β-catenin signaling pathways in colonic cells.
1. Introduction
RNA terminal phosphate cyclase B (RTCB), also known as FAAP, HSPC117, C22orf28, and D10Wsu52e, is a ligase that specifically connects the 2′,3′-cyclic phosphate and 5′-hydroxyl terminus of RNA [1,2]. RTCB is a highly conserved protein with a unique structure. It is present in archaea, bacteria, and animals but absent in plants and fungi [3]. In archaea and mammals, RTCB appears to serve as a catalyst in tRNA splicing [2,4]. In eukaryotes, RTCB is also involved in the unfolded protein response (UPR) by influencing the splicing of Xbp1 mRNA [5].
RTCB has been shown to play a significant role in multiple physiological processes. In embryonic development, inhibition of RTCB in mouse embryos results in embryonic death and placental dysplasia [6]. In reproductive function, while worms can grow to adulthood but fail to generate oocytes after knockdown of Rtcb [7], mice have premature ovarian failure after conditional knockout of Rtcb [8], and RTCB is specifically highly expressed in the initial segment of the mouse epididymis [9]. In immune function, specific knockout of Rtcb in mouse B cells leads to abnormal cell proliferation and differentiation and disrupts the structure of the endoplasmic reticulum (ER), ultimately affecting the secretion of some antibodies [5]. In neuroprotection, RTCB could ameliorate damage to dopaminergic neurons in a worm model of Parkinson’s disease [10]. A previous study showed that RTCB is widely expressed in intestinal tissues [11]; however, its function is unknown.
Colitis is an inflammatory disease of colonic tissues induced by various factors. Inflammation extends from the rectum to the proximal colon from onset, causing persistent superficial mucosal inflammation of varying degrees [12]. Inflammatory bowel disease (IBD) includes ulcerative colitis (UC) and Crohn’s disease (CD). UC is most common in industrialized countries, and its incidence has been increasing in Asia [13,14]. The total incidence and prevalence of UC are reported to be 0.0012%‒0.0203% and 0.0076%‒0.245% per year, respectively [15]. The differences in incidence among races are more related to environment, diet, and lifestyle. There is no significant sex difference in UC patients [16]. The onset time of UC has a bimodal distribution, with the first peak at 20‒30 years old and the second peak at 50‒80 years old [17]. The MAPK, NF-κB and Wnt/β-catenin signaling pathways play pivotal roles in the pathogenesis of colitis and its associated disorders [18,19]. Alterations in these signaling pathways are commonly concurrent with the onset of colitis [20,21].
Loading authentic research manuscript (Pages 1–5)...
Peiyan Liu, Ruitao Zhang, Xiaotong Song, Xiaohua Tian, Yichao Guan, Licheng Li, Mei He, Chengqiang He, Naizheng Ding (2026). RTCB deficiency triggers colitis in mice by influencing the NF-κB and Wnt/β-catenin signaling pathways. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2023279
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is RTCB and why is it important in the colon?
RTCB (RNA terminal phosphate cyclase B) is a ligase involved in RNA processing and has been implicated in various physiological processes. This study reveals that RTCB is crucial for maintaining colonic homeostasis, as its deficiency leads to colitis in mice.
How does RTCB deficiency cause colitis in mice?
RTCB deficiency disrupts the colonic barrier and triggers inflammatory cell infiltration. Mechanistically, it activates the NF-κB pathway (increasing TNF-α, IL-8, p-p65) and suppresses the Wnt/β-catenin pathway (decreasing Wnt3a, β-catenin, LGR5), leading to colitis.
What are the key signaling pathways affected by RTCB knockout?
The study shows that RTCB knockout dysregulates both the NF-κB and Wnt/β-catenin signaling pathways in colonic cells, which are pivotal in colitis pathogenesis.
What is the significance of this study for colitis treatment?
The findings suggest that RTCB could be a potential therapeutic target for colitis, as its deficiency contributes to disease development through specific molecular mechanisms.
How was the RTCB knockout mouse model generated?
The researchers used a conditional knockout approach with LoxP sites flanking exon 4 of the Rtcb gene and UBC-CreERT2 mice for tamoxifen-inducible knockout in adulthood.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.